The World Health Organization Includes the Cardiovascular Polypill Developed by the Spanish National Centre for Cardiovascular Research and Ferrer in its List of Essential Medicines
The cardiovascular polypill developed by the Spanish National Centre for Cardiovascular Research (CNIC) and Ferrer has been included by the World Health Organization (WHO) in its List of Essential Medicines 1.
This cardiovascular polypill includes three active ingredients (acetylsalicylic acid, ramipril and atorvastatin) and has been proven to be effective in preventing cardiovascular events after a heart attack, reducing mortality from cardiovascular causes by 33%. This was evidenced by the SECURE 2 study, with results published in August 2022 in the New England Journal of Medicine 3 (NEJM).
“The SECURE results showed, for the first time, that the cardiovascular polypill developed by the CNIC and Ferrer achieves clinically relevant reductions in recurrent cardiovascular events in patients who have suffered a myocardial infarction,” said Dr. Valentín Fuster, principal investigator of the study, General Director of the CNIC, President of Mount Sinai Heart and Physician-in-Chief of Mount Sinai Hospital, New York.
As stated in the WHO report, “essential medicines are those that satisfy the priority health care needs of a population. They are intended to be available in functioning health systems at all times, in appropriate dosage forms, of assured quality and at prices individuals and health systems can afford.”
According to Oscar Pérez, Chief Marketing, Market Access and Business Development Officer at Ferrer, “the 33% reduction in cardiovascular mortality demonstrates the efficacy of treatment with Trinomia 4 compared to standard treatment. The inclusion of this therapeutic solution in the WHO's List of Essential Medicines confirms our aim to make a positive impact in society and is an important step in our mission to bring significant and differential value to people with cardiovascular disease.”
Currently, the cardiovascular polypill developed by the CNIC and Ferrer is marketed in 25 countries and the feasibility of extending its distribution to additional territories, including the United States, is under analysis.
2.- SECURE study - https://www.cnic.es/en/clinical-research
3.- Polypill Strategy in Secondary Cardiovascular Prevention, Castellano JM, Fuster V et al. New England Journal of Medicine (NEJM). 2022 Aug. (consult: https://www.nejm.org/doi/full/10.1056/NEJMoa2208275)
4.- Trinomia® data sheet: SUMMARY OF PRODUCT CHARACTERISTICS (https://www.ferrer.com/sites/default/files/2023-08/Trinomia_SmPC.pdf)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For more information:
+34 936 003 779
Communication Advisor at Ferrer
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Clarity AI Honored in Fast Company Magazine’s 2023 “Brands That Matter” List4.10.2023 10:24:00 EEST | Press release
Clarity AI, the leading sustainability technology platform, has been named to Fast Company’s prestigious annual list of “Brands That Matter” in 2023. With this list, Fast Company, the world's leading business media brand, aims to get beyond “corporate vision statements and management talking points” and recognize brands that “clearly generate enthusiasm among their customers, offering a model of what other brands should be aiming for, and what a brand, at its best, can achieve.” Clarity AI was selected among more than 1,000 entries for its contribution to allowing “companies, investors, and more to ensure they’re investing sustainably by tracking metrics ranging from data on the climate impact to gender equality and diversity on the executive boards of prominent companies.” Additionally, Fast Company highlights Clarity AI’s role in “improving artificial technologies and understanding the multitude of benefits they can offer.” Rebeca Minguela, Founder & CEO of Clarity AI, said: “We're h
Uusi kysely: 66% suomalaisista työntekijöistä haluaisi kotona työskentelystä lain suojaaman oikeuden4.10.2023 10:00:00 EEST | Tiedote
Yhteistyötä tukevia ratkaisuja tarjoavan tekniikkayrityksen Owl Labsin hiljattain toteuttama kysely selvittää pohjoismaisten työntekijöiden asennoitumista etätyöhön. The State of Hybrid Work Report 2023 -tutkimukseen osallistui 2 000 vastaajaa Suomesta, Ruotsista, Norjasta ja Tanskasta. Raportista selviää, että peräti 66% suomalaisista työntekijöistä haluaisi etätyöstä tehtävän lain suojaaman oikeuden. Tämä kertoo joustavien työolojen kasvavasta suosiosta. Tutkimuksen mukaan 63% kaikista pohjoismaisista työntekijöistä on samaa mieltä oikeudesta etätyöhön. Tuki etätyölle laillisena oikeutena jakautuu eri Pohjoismaissa seuraavasti: 65% ruotsalaisista, 63% norjalaisista ja 57% tanskalaisista työntekijöistä tukee ajatusta. Owl Labsin toimitusjohtaja Frank Weishaupt sanoo: “Pohjoismaisten työntekijöiden yksimielisyys kotona työskentelystä lain suojaamana oikeutena kertoo muutoksista työntekijöiden asenteissa työympäristöään kohtaan. Se vahvistaa, miten tärkeänä työn ja vapaa-ajan välistä ta
ABN AMRO and Motive Partners form strategic partnership4.10.2023 09:30:00 EEST | Press release
The move demonstrates a joint commitment from two sizable financial technology investors to support continued innovation and growth in the evolving fintech landscape. Motive Ventures, the early-stage venture arm of Motive Partners, will manage the ABN AMRO Ventures Fund (AAV), consisting of 15 early-stage companies. In addition, ABN AMRO will become a significant investor in Motive-managed vehicles. With funding in the financial services industry declining by 70% between 2021 and 2022, and numerous venture capitalists reducing their investment programmes, Motive Partners and ABN AMRO are charting a new course. Their partnership unites two leading venture platforms, each with decades of fintech expertise and a dedication to innovation in both financial services and venture capital. Their goal is to strengthen the fintech sector and boost innovation by bringing Motive Partners’ ecosystem and experts to the AAV portfolio and ABN AMRO’s broader network. Motive Ventures’ portfolio consists
Desktop Health Announces that Flexcera™ Smile Ultra+ is now Available in Europe, Following Recent Class IIa MDR Certification by the European Union4.10.2023 09:00:00 EEST | Press release
Desktop Health™, the trusted health care brand of Desktop Metal (NYSE:DM), announced that its popular Flexcera™ Smile Ultra+ dental resin, for 3D printing permanent and temporary restorations, is now available for purchase in Europe following its successful certification as a Class IIa medical device under the European Union Medical Device Regulation (MDR). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231004075864/en/ Desktop Health's Flexcera™ Smile Ultra+ dental resin for 3D printing permanent and temporary restorations is now available for purchase in Europe following its successful certification as a Class IIa medical device under the European Union Medical Device Regulation (MDR). (Photo: Business Wire) Flexcera Smile Ultra+ delivers exceptional strength, life-like aesthetics, and the long-term performance expected from a permanent restoration material. Already an FDA 510(k) Class II cleared material, Flexcera Smile U
Velsera to Showcase Seven Bridges Bioinformatics Platform at BioTechX Europe4.10.2023 08:03:00 EEST | Press release
Velsera, a global healthcare technology company offering a universal software platform to connect clinical care with discovery, is proud to announce its title sponsorship at BioTechX Europe in Basel, Switzerland, where it will showcase its industry-leading Seven Bridges bioinformatics platform. This conference is Europe’s largest congress covering diagnostics, precision medicine and digital transformation in pharmaceutical development and healthcare. One of the keynote presentations, sponsored by Velsera, will be on the topic of “Digital Transformation of Early Research at Novo Nordisk and Leveraging AI/ML for Drug Discovery", featuring Asli Ismihan Ozen, head of research engineering, digital science and innovation at Novo Nordisk. She takes the stage at 9:20 am on Wednesday, Oct. 4. Additionally, Jack DiGiovanna, Velsera’s senior vice president of science strategy, will present on “Unleashing the Power of Neoantigens”, with an insightful look at solving complex problems through intero
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom